bluebird bio (NASDAQ:BLUE) versus Immatics (NASDAQ:IMTX) Financial Comparison

Immatics (NASDAQ:IMTX) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Earnings and Valuation

This table compares Immatics and bluebird bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$58.44 million	16.03	-$104.98 million	($0.66)	-11.89
bluebird bio	$29.50 million	3.00	-$211.91 million	($1.87)	-0.24

Immatics has higher revenue and earnings than bluebird bio. Immatics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

64.4% of Immatics shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 1.4% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Immatics and bluebird bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	0	0	4	1	3.20
bluebird bio	2	6	2	0	2.00

Immatics presently has a consensus price target of $16.67, suggesting a potential upside of 112.31%. bluebird bio has a consensus price target of $2.46, suggesting a potential upside of 439.79%. Given bluebird bio’s higher probable upside, analysts clearly believe bluebird bio is more favorable than Immatics.

Volatility and Risk

Immatics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.

Profitability

This table compares Immatics and bluebird bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immatics	-47.94%	-15.90%	-9.38%
bluebird bio	-565.74%	-322.46%	-53.17%

Summary

Immatics beats bluebird bio on 12 of the 15 factors compared between the two stocks.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

About bluebird bio

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.